GSK plc 6-K, filed Jul 18, 2022
GSK plc (GSK)
6-K
2022-07-18
For: 2022-07-18
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on July 18, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued:
18 July 2022, London UK
Completion of GSK Share Consolidation
GSK plc
(LSE/NYSE: GSK) is pleased to announce that further to the Circular
and Notice of General Meeting published by GSK on 1 June 2022, and
following the announcements of 6 July 2022 that shareholder
approval was granted at the GSK General Meeting and of 18 July 2022
that GSK has completed the demerger of the Consumer Healthcare
business from the GSK Group to form Haleon, the consolidation of
GSK shares (the “GSK Share Consolidation”) will become
effective at 8.00 a.m. tomorrow (Tuesday 19 July
2022).
Admission
of GSK’s new ordinary shares to the premium listing segment
of the Official List of the Financial Conduct Authority
(“FCA”) and to trading on the London Stock Exchange's
Main Market for listed securities will take place at 8.00 a.m.
tomorrow.
Further
information on key dates in relation to the GSK Share Consolidation
is set out at the end of this announcement (“Expected
Timetable of Principal Events”) and can also be found in the
Circular to Shareholders published on 1 June 2022. The Circular is
available on GSK’s website at www.gsk.com/demerger.
The new
ordinary shares will be registered with:
|
ISIN number
|
GB00BN7SWP63
|
|
SEDOL number
|
BN7SWP6
|
As at
the record time of 8.00 p.m. (UK) on Monday 18 July 2022, the GSK
Share Consolidation applied a ratio of:
4 new ordinary shares for every 5 existing ordinary shares.
Fractional entitlements
Unless
a holding of existing ordinary shares at the record time was
exactly divisible by the denominator in the consolidation ratio, a
shareholder will have a fractional entitlement to a new ordinary
share. Fractional entitlements that have arisen from the GSK Share
Consolidation will be aggregated and the resulting new ordinary
shares will be sold in the open market, as soon as practicable, at
the best price reasonably obtainable, and the net proceeds will be
paid to each relevant shareholder according to his or her
entitlement.
Total number of voting rights
Following
the Issuance and the GSK Share Consolidation, and in accordance
with the requirements of the FCA’s Disclosure Guidance and
Transparency Rule 5.6.1A, GSK hereby notifies the market that
GSK’s issued share capital as at 8.00 am on Tuesday 19 July
2022 will consist of 4,311,276,836 ordinary shares of 31¼
pence each (including 243,924,760 ordinary shares held in
treasury). Therefore, the total number of voting rights in GSK as
at 19 July 2022 is 4,067,352,076.
The
above figure may be used by shareholders and others with
notification obligations as their denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the GSK Group under
the FCA's Disclosure Guidance and Transparency Rules. Notifications
may be sent to company.secretary@gsk.com.
Dividends
GSK has
previously stated that it expected to declare a 27p per share
dividend for the first half of 2022, a 22p per share dividend for
the second half of 2022 and a 45p per share dividend for 2023, but
that these targeted dividends per share would increase in step with
the GSK Share Consolidation to maintain the same aggregate dividend
pay-out in absolute Pound Sterling terms. Accordingly, using the
consolidation ratio, GSK’s expected dividend for the second
quarter of 2022 converts to 16.25p per new ordinary share (taking
into account the dividend of 14p per share paid for the first
quarter of 2022), the expected dividend for the second half of 2022
converts to 27.5p per new ordinary share and the expected dividend
for 2023 converts to 56.25p per new ordinary share. GSK expects to
publish its results for the second quarter of 2022 on Wednesday 27
July 2022 which will confirm the dividend to be declared for that
quarter.
American Depositary Shares (ADSs)
The GSK
Share Consolidation will not result in a change to the ratio of GSK
shares represented by each GSK ADS. However, following the GSK
Share Consolidation becoming effective, the existing GSK shares
held by the ADS Depositary will be replaced with a smaller number
of new GSK shares. As a result, GSK ADS holders will, upon
cancellation of their existing GSK ADSs, be issued with and receive
4 new GSK ADSs for every 5 existing GSK ADSs.
It is
expected that “regular-way” trading with respect to
existing GSK ADSs will end at market open on Tuesday 19 July 2022
and that “regular-way” trading with respect to new GSK
ADSs will commence on the New York Stock Exchange (the
“NYSE”) at market open on Friday 22 July 2022. In
addition, it is expected that new GSK ADSs will begin trading on a
“when-issued” basis on the NYSE from market open on
Tuesday 19 July 2022 and continue up to and including Thursday 21
July 2022. New GSK ADSs will trade under the CUSIP number
37733W204.
Further
details on the impact of the GSK Share Consolidation on GSK ADS
holders are provided in the Circular, which is available on
GSK’s website at www.gsk.com/demerger.
Victoria
Whyte
Company
Secretary
18 July
2022
Expected Timetable of Principal Events
The
times and dates set out in the timetable below and throughout this
announcement are indicative only and based on GSK’s current
expectations and may be subject to change without further
notice.
|
Event
|
Time and date(1)
|
|
GSK
Admission and commencement of dealings in New GSK Shares on the
LSE
|
8.00
a.m. on Tuesday 19 July 2022
|
|
CREST
accounts credited in respect of New GSK Shares in uncertificated
form
|
As soon
as practicable after 8.00 a.m. on Tuesday 19 July 2022
|
|
Admission
and commencement of dealings in new GSK ADSs on the
NYSE
|
9.30
a.m. New York City time on Friday 22 July 2022
|
|
Opening
of the GSK ADS issuance and cancellation books(2)
|
8.00
a.m. New York City time on Monday 25 July 2022
|
|
Latest
date for despatch of:
- definitive share
certificates (where applicable) for New GSK Shares in certificated
form to Qualifying Shareholders on the GSK Share
Register
|
By
Monday 1 August 2022
|
|
- CSN statements for
GSK CSN(3)
|
By
Monday 1 August 2022
|
|
Posting
of payment advice, CREST accounts credited or payment by electronic
payment in respect of fractional entitlements arising from the GSK
Share Consolidation
|
Week
commencing Monday 1 August 2022
|
Notes
(1)
Unless otherwise
indicated, all references to time in this timetable are to UK
time.
(2)
The Depositary will
suspend the issuance and cancellation of GSK ADSs from Thursday 14
July 2022 until Monday 25 July 2022. This means that during this
time, you will not be able to convert your GSK ADSs into GSK
Shares, surrender your GSK ADSs and receive underlying GSK Shares,
or deposit your GSK Shares and receive GSK ADSs. However, the
closing of the issuance and cancellation books does not impact
trading, and you may continue to trade your GSK ADSs during this
period.
(3)
For CSN
Shareholders who have a Shareview Portfolio account, and have not
elected for paper statements to be issued to them, the CSN
statements will only be made available electronically via their
account.
About GSK
GSK is
a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com/en-gb/company/
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Madeleine
Breckon
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK’s Q1 Results for
2022 and any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
18, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|